Slide 1: OraSure 1Q22 Earnings
OraSure 1Q22 Earnings May 10, 2022 EXHIBIT 99.2
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or
Slide 3: 1Q22 Financial Results
1Q22 Financial Results FINANCIAL METRIC 1Q22 RESULTS 1Q21 RESULTS YEAR-OVER-YEAR GROWTH RATE Quarterly Revenue $67.7 million $58.6 million 16% Diagnostics Revenue $38.3 million $14.5 million 163% Diagnostics Revenue W/O COVID-19 Products $16.2 million $14.5 million 11% Molecular Solutions Revenue $2
Slide 4: 1Q22 Diagnostic Business Unit Results
1Q22 Diagnostic Business Unit Results Q4 2021 % vs PY Total DX BU $38.3M +163% Core DX $16.2M 11% Core DX US $10.5M 7% Core DX OUS $5.6M 20% COVID-19 $22.1M NM
Slide 5: Significant Improvements in Production Process
Significant Improvements in Production Process 30% <1% Early Jan. 2022 April 2022 >4 Fold Increase in Test Volume Finished Goods Scrap Rate 1. Eliminated manual handling steps 2. Changed settings on robotic assembly 3. Optimized settings on automated striping and assay card assembly machines 4. Sign
Slide 6: US Government Continues Support for InteliSwab
US Government Continues Support for InteliSwab® Continued Procurement as part of OraSure’s Defense Logistics Agency/HHS contract Consistent ongoing testing needed in congregate settings Evens out demand, enables shipments even during low points between surges
Slide 7: InteliSwab Recent Expansions
InteliSwab® Recent Expansions InteliSwab® detects Omicron with same limit of detection as other variants of concern and original Wuhan strain Pediatric indication for use in children ages 2-14 when performed by an adult Launched the reporting app, InteliSwab ® Connect
Slide 8: Molecular Solutions Business Unit Results
4Q21 and FY21 Molecular Solutions Business Unit Results FINANCIAL METRIC 1Q22 1Q21 YEAR-OVER-YEAR GROWTH RATE Quarterly Core Molecular Solutions $20.5 million $16.1 million 28% Quarterly COVID-19 Kits $8.9 million $28.0 million (68%) Total Molecular Solutions $29.4 million $44.0 million (33%)
Slide 9: Molecular Solutions COVID-19 Kit Revenue
Molecular Solutions COVID-19 Kit Revenue Increasing transition from central lab testing to POC testing options GOING FORWARD: International expansion Broader launch in viral surveillance
Slide 10: Meta-transcriptome Launch and FDA Clearance for Gut Kit
Meta-transcriptome Launch FDA Clearance for Gut Kit Enabling Multi-Omic Discovery and Diagnostics Through Innovation Launch of RNA/DNA Kit Launch of MetaGene Canine
Slide 11: Consolidated Revenue by Quarter
Consolidated Revenue by Quarter Revenue (in mil.) Record Revenue in 1Q22 Record revenue in 1Q22
Slide 12: Financial Results
Financial Results
Slide 13: Summary
Summary Significant improvements made in InteliSwab production and manufacturing efficiency Strong double-digit core growth in both business units 36% growth in molecular kits year-over-year Focused on continued efficiency and expense reduction Smart Science Made Simple
Slide 14: Q&A
Q&A OraSure Technologies oNAgenoTeK” Diversigen’ Wnovosanis